ObsEva SA (NASDAQ:OBSV) has earned an average recommendation of “Buy” from the six analysts that are currently covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have issued a report on the stock in the last year is $18.83.

OBSV has been the subject of several recent research reports. Zacks Investment Research upgraded ObsEva SA from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. HC Wainwright set a $27.00 price target on ObsEva SA and gave the company a “buy” rating in a research note on Wednesday, August 16th. Leerink Swann reiterated an “outperform” rating and issued a $18.00 price target on shares of ObsEva SA in a research note on Wednesday, August 16th. Finally, Royal Bank Of Canada assumed coverage on ObsEva SA in a research note on Thursday, September 14th. They issued an “outperform” rating and a $22.00 price target for the company.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Paloma Partners Management Co bought a new stake in ObsEva SA during the first quarter worth $131,000. Sphera Funds Management LTD. lifted its stake in ObsEva SA by 9.7% during the second quarter. Sphera Funds Management LTD. now owns 231,497 shares of the company’s stock worth $1,979,000 after purchasing an additional 20,411 shares during the last quarter. Sectoral Asset Management Inc lifted its stake in ObsEva SA by 181.9% during the second quarter. Sectoral Asset Management Inc now owns 212,831 shares of the company’s stock worth $1,820,000 after purchasing an additional 137,331 shares during the last quarter. Finally, VHCP Management II LLC bought a new stake in ObsEva SA during the second quarter worth $1,283,000. Hedge funds and other institutional investors own 48.46% of the company’s stock.

ObsEva SA (NASDAQ:OBSV) last issued its quarterly earnings results on Tuesday, August 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.13). During the same quarter last year, the company posted ($0.30) earnings per share.

ILLEGAL ACTIVITY NOTICE: This story was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/11/03/obseva-sa-obsv-given-consensus-recommendation-of-buy-by-brokerages.html.

ObsEva SA Company Profile

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

Analyst Recommendations for ObsEva SA (NASDAQ:OBSV)

Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.